Table 2.
Clinical and pathological characteristics of enrolled patients.
| Groups | ||
|---|---|---|
| 2–3 years tamoxifen (ST group) n = 1345 | 10 year tamoxifen (extended group) n = 2485 | |
| Age (years) | ||
| Median (IQR) | 63 (57–68) | 62 (57–68) |
| Years of initial treatment | ||
| <1990 | 848 (63.0%) | 1614 (64.9%) |
| ≥1990 | 496 (36.9%) | 863 (34.7%) |
| Unknown | 1 (0.07%) | 8 (0.3%) |
| Type of breast surgery | ||
| No surgery | 48 (3.6 %) | 78 (3.1%) |
| Lumpectomy | 579 (43.0%) | 1265 (50.9%) |
| Mastectomy | 715 (53.2%) | 1130 (45.5%) |
| Unknown | 3 (0.2%) | 12 (0.5%) |
| Tumor size | ||
| pT0 | 31 (2.3%) | 102 (4.1%) |
| pT1 | 288 (21.4%) | 633 (25.5%) |
| pT2 | 719 (53.5%) | 1209 (48.7%) |
| pT3-4 | 204 (15.2%) | 352 (14.2%) |
| Unknown | 103 (7.7%) | 189 (7.6%) |
| Nodal status | ||
| Negative | 381 (28.3%) | 846 (34.0%) |
| Positive | 961(71.5%) | 1634 (65.8%) |
| Unknown | 3 (0.2%) | 5 (0.2 %) |
| Estrogen receptor status | ||
| Positive | 806 (59.9%) | 1596 (64.2%) |
| Negative | 180 (13.4%) | 248 (10.0%) |
| Unknown | 359 (26.7%) | 641 (25.8%) |
| Tamoxifen dosage | ||
| ≤20 mg | 427 (31.8%) | 1355 (54.5%) |
| > 20 mg | 876 (65.1%) | 1108 (44.6%) |
| Unknown | 42 (3.1%) | 22 (0.9%) |
| Adjuvant chemotherapy | ||
| No | 956 (71.1%) | 1674 (67.4%) |
| Yes | 384 (28.6%) | 785 (31.6%) |
| Unknown | 5 (0.3%) | 26 (1.0%) |
| Adjuvant radiotherapy | ||
| No | 184 (13.7%) | 296 (11.9%) |
| Yes | 1158 (86.1%) | 2175 (87.5%) |
| Unknown | 3 (0.2%) | 14 (0.6%) |
IQR interquartile range.